Iobenguane sulfate

Iobenguane sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono (ADP-ribosylation) . Radioiodinated Iobenguane sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. (In Vitro) :Iobenguane sulfate (MIBG sulfate) (2-20 μg/ml; 72 hours) inhibits cell growth in a panel of human and mouse leukemia, fibrosarcoma, melanoma, and neuroblastoma cell lines.Iobenguane sulfate (MIBG sulfate) is a potent affector of endogenous mono (ADP-ribosyl) transferases of turkey and human erythrocyte membranes, exerting its effect in the μM concentration range. (In Vivo) :Iobenguane sulfate (MIBG hemisulfate) (20 mg/kg; i.p.; daily on days 3-6) shows antitumor activity.The survival of male strain AF mice inoculates with N1E115 neuroblastoma and treats according to NIH protocols for new drug testing with 9 daily injections of Iobenguane sulfate (40 mg/kg), Marking prolongation of sugvival but no cures were observed.Iobenguane sulfate testes for its toxicity on male strain AF (N1Ell5) mice with 5 daily injections. At 50 mg/kg body weight, all animals died after 1-4 doses and 4/16 animals died on a schedule of 44 mg/kg.

87862-25-7

MIBG sulfate

>98% (HPLC)

DMSO:100 mg/mL (308.52 mM; Need ultrasonic)

NC (NCC1=CC=CC (I) =C1) =N.O=S (O) (O) =O.[1/2]

C8H10IN3.1/2H2O4S

324.13

Storage temperature: -20°C. Stability: ≥ 2 years